Catalyst Pharmaceuticals, Inc. (CPRX)

Catalyst Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	398.2	214.2	140.83	119.07	102.31
Revenue Growth (YoY)	85.90%	52.10%	18.27%	16.39%	20361.20%
Cost of Revenue	51.97	34.39	21.88	17.04	14.76
Gross Profit	346.24	179.81	118.95	102.03	87.55
Selling, General & Admin	133.71	57.09	49.63	44.23	36.88
Research & Development	93.15	19.79	16.94	16.5	18.84
Other Operating Expenses	32.57	1.1	0	0	0
Operating Expenses	259.43	77.97	66.56	60.73	55.72
Operating Income	86.81	101.84	52.39	41.3	31.82
Other Expense / Income	-7.7	-2.88	-0.28	-0.59	-1.59
Pretax Income	94.51	104.72	52.67	41.89	33.41
Income Tax	23.1	21.64	13.19	-33.09	1.53
Net Income	71.41	83.08	39.48	74.98	31.88
Net Income Growth	-14.05%	110.42%	-47.35%	135.24%	-
Shares Outstanding (Basic)	106	103	103	104	103
Shares Outstanding (Diluted)	114	111	108	106	106
Shares Change	2.13%	3.32%	1.46%	0.21%	3.30%
EPS (Basic)	0.67	0.80	0.38	0.72	0.31
EPS (Diluted)	0.63	0.75	0.37	0.71	0.30
EPS Growth	-16.00%	102.70%	-47.89%	136.67%	-
Free Cash Flow	143.37	116.02	59.35	45.02	34.59
Free Cash Flow Per Share	1.35	1.12	0.57	0.43	0.34
Gross Margin	86.95%	83.94%	84.46%	85.69%	85.57%
Operating Margin	21.80%	47.54%	37.20%	34.69%	31.11%
Profit Margin	17.93%	38.79%	28.03%	62.97%	31.16%
Free Cash Flow Margin	36.00%	54.16%	42.14%	37.81%	33.81%
Effective Tax Rate	24.44%	20.66%	25.03%	-79.00%	4.59%
EBITDA	127.65	106.21	53.15	42.78	33.71
EBITDA Margin	32.06%	49.58%	37.74%	35.92%	32.95%
Depreciation & Amortization	33.14	1.49	0.48	0.89	0.3
EBIT	94.51	104.72	52.67	41.89	33.41
EBIT Margin	23.73%	48.89%	37.40%	35.18%	32.66%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).